Monalizumab, cetuximab and durvalumab in first-line treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): A phase II trial

被引：10
|
作者：
Colevas, D. A. [1 ]
Misiukiewicz, K. [2 ]
Pearson, A. T. [3 ]
Fayette, J. [4 ]
Bauman, J. R. [5 ]
Cupissol, D. [6 ]
Saada-Bouzid, E. [7 ]
Adkins, D. R. [8 ]
Marie, D. B. [9 ]
Cornen, S. L. [9 ]
Andre, P. [9 ]
Carrette, F. [9 ]
Rotolo, F. [9 ]
Boyer Chammard, A. [9 ]
Cohen, R. B. [10 ]
机构：
[1] Stanford Canc Ctr, Med Oncol, Stanford, CA 94305 USA
[2] Mt Sinai Hosp, Med Oncol, New York, NY 10029 USA
[3] Univ Chicago, Med Oncol, Chicago, IL 60637 USA
[4] Ctr Leon Berard, Med Oncol, Lyon, France
[5] Fox Chase Canc Ctr Main Campus, Dept Hematol Oncol, Philadelphia, PA 19140 USA
[6] Inst Canc Montpellier, Med Oncol, Montpellier, France
[7] Ctr Antoine Lacassagne, Med Oncol, Nice, France
[8] Washington Univ, Med Oncol, Sch Med, St Louis, MO 63130 USA
[9] Innate Pharma, Res & Dev, Marseille, France
[10] Abramson Canc Ctr, Ctr Head & Neck Canc, Philadelphia, PA USA
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.10.142
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
123MO
引用
收藏
页码：S1432 / S1432
页数：1
相关论文
共 50 条
  • [1] Results of a phase II study evaluating monalizumab in combination with cetuximab in previously treated recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN)
    Fayette, J.
    Lefebvre, G.
    Posner, M. R.
    Bauman, J.
    Salas, S.
    Even, C.
    Saada-Bouzid, E.
    Seiwert, T.
    Colevas, D.
    Calmels, F.
    Zerbib, R.
    Chammard, A. Boyer
    Cohen, R.
    ANNALS OF ONCOLOGY, 2018, 29 : 374 - 374
  • [2] Phase II trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M SCCHN)
    Obara, G.
    Sun, J.
    Loo, D.
    Bohac, C.
    ANNALS OF ONCOLOGY, 2021, 32 : S814 - S814
  • [3] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): First results of phase II trial GORTEC 2008-03.
    Guigay, J.
    Fayette, J.
    Dillies, A.
    Sire, C.
    Kerger, J. N.
    Tennevet, I.
    Machiels, J. H.
    Zanetta, S.
    Pointreau, Y.
    Le Moal, L. Bozec
    Ribere, L. Brugel
    Henry, S.
    Temam, S.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [4] Cetuximab, docetaxel, and cisplatin (TPEx) as first-line treatment in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): Final results of phase II trial GORTEC 2008-03.
    Guigay, Joel
    Fayette, Jerome
    Dillies, Anne-Francoise
    Sire, Christian
    Kerger, Joseph N.
    Tennevet, Isabelle
    Machiels, Jean-Pascal H.
    Zanetta, Sylvie
    Pointreau, Yoann
    Le Moal, Laurence Bozec
    Ribere, Lydia Brugel
    Henry, Stefanie
    Temam, Stephane
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [5] Cetuximab with or without sorafenib in recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN)
    Gilbert, Jill
    Schell, Michael J.
    Zhao, Xiuhua
    Murphy, Barbara A.
    Tanvetyanon, Tawee
    Hayes, David N.
    Haigentz, Missak
    Saba, Nabil F.
    Nieva, Jorge J.
    Perez, Jimena
    Bishop, Justin A.
    Chung, Christine H.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [6] Phase 2 trial of enoblituzumab plus retifanlimab or tebotelimab in first-line treatment of patients (pts) with recurrent or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN).
    Obara, Grzegorz
    Sun, Jichao
    Loo, Deryk
    Bohac, Gerry C.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [7] Cetuximab in recurrent/metastatic (R&M) squamous cell carcinoma of the head and, neck (SCCHN) refractory to first-line platinum-based therapies.
    Vermorken, JB
    Bourhis, J
    Trigo, J
    Kies, M
    Leon, X
    Mueser, M
    Amellal, N
    Schueler, A
    Baselga, J
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 501S - 501S
  • [8] Cetuximab in combination with methotrexate (MTX) as first-line treatment in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): A phase Ib randomized phase II study versus single agent MTX
    Ham, J.
    Meerten, E.
    Fiets, E.
    Mc Haaglanden, F. Jeurissen
    Slingerland, M.
    van der Graaf, W. T. A.
    van Herpen, C. M. L.
    Beerepoot, L. V.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Cetuximab, fluorouracil (5-FU), cisplatin, and docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCiD).
    Knoedler, Maren
    Dietz, Andreas
    Gauler, Thomas Christoph
    Gruenwald, Viktor
    Stoehlmacher, Jan
    Knipping, Stephan
    Guntinas-Lichius, Orlando
    Frickhofen, Norbert
    Schroeder, Michael
    Maschmeyer, Georg
    Rethwisch, Volker
    Haxel, Boris
    Keilholz, Ulrich
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [10] Cetuximab, Fluorouracil (5-FU), Ciplatin and Docetaxel as first-line treatment in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Interim results of a randomized phase II clinical trial (CeFCID).
    Knoedler, M.
    Dietz, A.
    Gauler, T.
    Stoehlmacher-Williams, J.
    Gruenwald, V
    Rethwisch, V.
    Frickhofen, N.
    Haxel, B.
    Schroeder, M.
    Knipping, S.
    Maschmeyer, G.
    Guntinas-Lichius, O.
    Keilholz, U.
    ONKOLOGIE, 2013, 36 : 94 - 94
12345